A microarray (LungCaGxE), based on Illumina BeadChip technology, was developed for high-resolution genotyping of genes that are candidates for involvement in environmentally driven aspects of lung cancer oncogenesis and/or tumor growth. The iterative array design process illustrates techniques for managing large panels of candidate genes and optimizing marker selection, aided by a new bioinformatics pipeline component, Tagger Batch Assistant. The LungCaGxE platform targets 298 genes and the proximal genetic regions in which they are located, using ϳ13,000 DNA single nucleotide polymorphisms (SNPs), which include haplotype linkage markers with a minimum allele frequency of 1% and additional specifically targeted SNPs, for which published reports have indicated functional consequences or associations with lung cancer or other smoking-related diseases. The overall assay conversion rate was 98.9%; 99.0% of markers with a minimum Illumina design score of 0.6 successfully generated allele calls using genomic DNA from a study population of 1873 lung-cancer patients and controls.
INTRODUCTION
Lung cancer is the leading cause of cancer death for men and women in the United States. The American Cancer Society estimates that in 2013, there will be 228,190 new cases (118,080 in men; 110,110 in women) and 159,480 deaths. 1 Many patients present with disease that is too advanced to treat successfully with surgery and the current portfolio of drugs. Identification of those at highest risk of disease would facilitate earlier diagnosis and therapeutic intervention, with consequent reduced mortality and longer survival time. Risk identification techniques would also support preventative screening and targeted interventions, such as smoking-cessation programs leading to reduced incidence. Given the huge number of new lung cancer cases that occur each year, the impact of such interventions would be significant even if applicable only to an etiologically distinct subset of all cases.
As the majority (up to 90%) of lung cancers occurs in smokers, but only a minority (ϳ10%) of smokers get the disease, 2 it is likely that significant gene/phenotype/environment interactions exist. 3 Although tobacco smoke is the main etiologic agent, 4 the long latency between exposure and disease, the multistep nature of neoplastic transformation, 5 and the low, 10-year lung-cancer risk of elderly, life-long heavy smokers (15%) 6 suggest that factors other than tobacco-associated carcinogens modify risk. These likely include environmental variables, 7 functional genetic polymorphisms, 8, 9 and differential expression of genes that interact with such variables. 10 Strategies to identify associations between genetic variants and diseases, such as lung cancer, include genotyping sequence polymorphisms that are distributed throughout the genome or that occur in specifically targeted genes of interest. Compared with genome-wide approaches, genotyping a focused set of single nucleotide polymorphisms (SNPs) for high-resolution haplotype mapping boosts analysis power for identifying single gene and gene family effects with statistical significance. Targeted, redundant genotyping of candidate genes further enables the analysis of additional variables, such as environmental factors, without a requirement to sample extremely large populations. However, designing a genotyping assay that adequately covers each candidate gene with a sufficiently large number of markers poses a challenge for this approach, especially when interrogating many genes in parallel. Standard genome-wide platforms, such as Affymetrix (Affymetrix, Santa Clara, CA, USA) or Illumina microarrays (Illumina, San Diego, CA, USA), provide predesigned collections of genotyping assays but rarely include enough markers to approach saturation of any given target gene. Microarray vendors therefore offer custom manufacturing options to allow researchers to create comprehensive panels of assays that satisfy the requirements of high-resolution genotyping. We describe a process that connects publicly available SNP catalogs with commercial assay design interfaces, using a new bioinformatics tool that assists with the management of large collections of genes and their haplotypetagging (HapTag) SNPs. This process was used to demonstrate the rapid and iterative design of a customgenotyping microarray for studying lung cancer.
MATERIALS AND METHODS

Target Selection
Investigators in our consortium contributed prioritized lists of genes potentially relevant to environmentally mediated biological processes leading to lung cancer. Candidate genes included modulators of and checkpoints within pathways hypothesized to respond to tobacco toxins and environmental factors that may promote oncogenesis, as well as those that may act in concert with environmental factors to support tumor survival, progression, and growth. These genes fell into broad categories, including tobaccospecific nitrosamine [particularly nitrosaminoketone (NNK)] activation and detoxification, polycyclic aromatic hydrocarbon (PAH) activation and detoxification, repair of NNK-and PAH-attributable DNA damage, oxidative stress, inflammatory signaling and processes of immune regulation, steroid hormone metabolism and signaling, nicotine addiction and smoking behavior, and folate transport and metabolism. For each individual gene, HapTag SNPs and genetic polymorphisms known to affect function or shown previously to be associated with risk for lung cancer were sought and if found, incorporated into the final microarray design.
Target sources included extensive literature searches, Ingenuity Pathway Analysis (http://www.ingenuity.com), Database for Annotation, Visualization, and Integrated Discovery (DAVID) Bioinformatics Resources, 11, 12 and ongoing research in investigators' laboratories.
SNP Selection
All targeted genes/chromosomal regions were uploaded to the Assay Design Tool (http://support.illumina.com/tools. ilmn; Illumina) for retrieval of all iSelect Infinium database SNPs within each targeted region, as well as from 15 kb sequences flanking the gene-boundary coordinates. Known polymorphisms from the target-selection phase were also queried by reference SNP (rs) number from database of SNPs (dbSNP; http://www.ncbi.nlm.nih.gov/snp/), or uploaded as custom sequences if polymorphisms were unrecognized by iSelect or not annotated in dbSNP. Independently, the targeted genes and regions were analyzed using Tagger (http://www.broadinstitute.org/mpg/tagger/server. html, and International HapMap Project haplotype mapping databases therein) 13 with the following parameters in all combinations: HapMap panels of Utah (U.S.A.) residents of northern and western European ancestry (CEU) and residents of Ibadan, Nigeria of Yoruban ancestry (YRI); SNP minimum allele frequencies 5% and 1%; Tagger mode pairwise and aggressive; SNP r2 threshold 0.8; and default settings for all other parameters. The Tagger online interface does not support batch queries using gene symbols, so we created the Tagger Batch Assistant (http:// www.bioinformatics.upenn.edu/tagtool/batch.html) as a tool for automated processing of large query lists and management and formatting of the output data.
The retrieved iSelect SNPs were filtered to retain markers with an Infinium design score Ն0.6 (a 60% probability of conversion, i.e., successful genotyping assays for that SNP), and the subset corresponding to selected HapTag SNPs from Tagger was identified. No Infinium design score limits were imposed on functional SNPs from the target selection phase. A panel of 357 ancestry informative markers was included (http://support.illumina.com/array/array_kits/dna_test_panel. ilmn, Illumina catalog GT-17-222).
Genotyping
DNA was extracted from whole-blood samples or buffycoat fractions using Chemagic DNA purification kits and a Chemagen Magnetic Separation Module I robot (Chemagen/PerkinElmer, Baesweiler, Germany). DNA qualitycontrol checks included A260/280 and E-Gel electrophoresis (Invitrogen, Life Technologies, Grand Island, NY, USA), and DNA samples (nϭ1873) were normalized to 50 ng/ul and used for genotyping assays. Genotyping was conducted using the iScan system (Illumina), according to the manufacturer's protocols. 14 The Infinium assay amplified and fragmented 200 ng genomic DNA, which was then hybridized to our LungCaGxE iSelect HD Custom BeadChips containing 24 arrays/BeadChip and 13,308 assayed SNPs/array. Four negative control (no DNA) arrays were processed, and 43 samples were processed twice to check assay consistency. Data from scanned BeadChips were processed in Illumina GenomeStudio for signal quantitation, quality control, and genotype assignments.
The research described does not involve animals. Blood samples from human subjects were collected with their informed consent for research use, including genetic analyses. This study was approved by Institutional Review Boards at the University of Pennsylvania, Pennsylvania State University, Temple University, and Fox Chase Cancer Center.
RESULTS
Tagger Batch Assistant
The online Tagger Batch Assistant tool was designed with two components: one for rapid retrieval of genomic coordinates for large lists of genes and another for managing Tagger output files that result from a batch query using genomic coordinates. Starting with a list of official National Center for Biotechnology Information gene symbols, the tool supports queries of several human genomebuild versions, concatenation or separation of overlapping genes, and rules for flanking regions that allow the addition of sequences adjacent to gene coordinates. Multiple choices are available for the amount of flanking sequences added, and rules can be stacked to vary the flanking regions by gene length. The output file can be reviewed in text or spreadsheet formats and is configured for uploading to the Tagger query interface. After receiving compressed Tagger results files, the tool supports automated merging of the user's annotated gene query lists with the corresponding Tagger results.
Assembly of Target Gene Panel
Project investigators identified 298 genes in pathways for which genetically mandated differential interactions with environmental factors leading to lung cancer were deemed to be biologically plausible. These pathways included those supporting or mediating carcinogen effects (i.e., nitrosamine and PAH activation and detoxification), oxidative stress, DNA damage repair, inflammation or immunesystem monitoring, estrogen, and other steroid hormone processes, nicotine addiction/smoking behavior, and folate metabolism. Target genes were chosen by examining previous literature, established molecular pathways, and gene interactions and sequence polymorphisms known to affect the functions of genes involved in lung tumor oncogenesis or responses to environmental factors that may impact lung cancer (Table 1) . Confirmatory DAVID annotation analyses were performed on the final gene list to summarize the categories represented from Online Mendelian Inheritance in Man (OMIM) Disease, Kyoto Encyclopedia of Genes and Genomes (KEGG) Pathway, Gene Ontology (GO) Molecular Function, and GO Biological Process databases (Supplemental Table 1 ). As expected, the final target panel was confirmed as being enriched for genes associated with risk for lung cancer, folate-sensitive phenotypes, hormone synthesis and signaling, oxidative stress responses, DNA repair, detoxification and metabolism of complex molecules, and apoptosis. Cross-category annotation indicates that the panel is coincidentally enriched for genes involved in schizophrenia, trichothiodystrophy, myocardial infarction, reproductive development, and various neurological processes.
Comparison of Pairwise and Multimarker Tagger Analyses
With the use of dbSNPs for the CEU and YRI populations, Tagger analysis was performed initially to predict marker HapTag SNPs that cover polymorphisms with minimum minor allele frequency (MAF) of 5% and then repeated for MAF Ͼ1%. Two Tagger algorithms were compared: pairwise modeling, in which a HapTag marker reports its own genotype and predicts the genotype of one linked SNP, and "aggressive" multimarker modeling, in which the combined genotypes of one to three HapTags report the local haplotype and predict the genotype(s) of one or more linked SNPs. 13, 15, 16 The resulting number of HapTags calculated for each gene is shown in Table 1 . At MAF Ͼ1%, pairwise modeling produced a g/h ratio of 1.92 (gϭmeasuredϩpredicted genotypes; hϭHapTag markers), and multimarker modeling resulted in 2.38 g/h for the same number of genotypes.
Genotyping Array Design and Assay Performance
Tagger multimarker-predicted HapTags with MAF Ͼ1% were filtered for iSelect Infinium design scores Ն0.6. TLR5 had no multimarker HapTags, so pairwise HapTags were selected; CCR2, UGT2B15, and GSTT1 had no HapTags, so marker SNPs were manually identified. To avoid exceeding the marker capacity set by our microarray manufacturing budget, the low-priority genes, ALPL, TNS1, GAB1, HHIP, DBH, and PTGIS, were dropped, and HapTag coverage of GPR126 was reduced to 85%. With the addition of specifically targeted functional SNPs and published marker SNPs, 12,890 genomic SNPs were compiled for the final design of the LungCaGxE array with average and median intermarker distances of 5958 bp and 1093 bp, respectively. Sixty-one mitochondrial DNA SNPs were included to target MT-COI, as well as 357 ancestry informative markers for a total of 13,308 genotyping markers on the array. All markers and their sequences, coordinates, and targeted genes are provided in Supplemental Table 2 .
Genotyping assays were performed on 1873 DNA samples from lung-cancer patients and controls using LungCaGxE microarrays. Forty-seven samples had a SNP assay call rate Ͻ99.0%. If these samples are excluded, SNP assays with an Infinium design score of at least 0.6 produced unambiguous genotype calls in 99.03% of the attempted reactions (Fig. 1) . Targeted functional SNPs with a design score Ͻ0.6 generated genotype calls in 84.96% of the attempted reactions; the average genotyping rate for SNPs with recognized rs numbers in the Illumina database was 99.09%, whereas the rate for SNPs submitted as custom sequences was 96.16% (design score Ͼ0.6 in both sets).
DISCUSSION
The advancement of array-based SNP genotyping technologies has led to genome-wide association studies (GWAS), in which genetic markers distributed evenly throughout the genome 17 (or covering predicted haplotypes throughout the genome 14 ) are tested for statistically significant association with a phenotype. Arrays offer advantages for GWAS over current deep-sequencing methods, including lower cost, faster assay turnaround and sample throughput, and easier data processing. However, the success of proxy markers depends on linkage to causal but unmeasured genetic variants, and even the highest capacity arrays of over 5 million SNPs may not cover rare variants or diverse populations well. Whole-genome or exome sequencing directly detects causal variants and polymorphism types beyond bi-allelic single nucleotides and does not rely on linked markers for statistical analysis. Whether deployed on SNP arrays or deep sequencing platforms, the primary concern for whole-genome assays is statistical power. Rare variants, multiple causes for the same phenotype, intergenic and multigene effects, and genetically mandated differential interactions between genes and environmental variables can all combine with multiple testing correction requirements to drive study population sizes to thousands or tens of thousands of subjects to adequately power GWAS. [18] [19] [20] [21] Projects of this scale are an expensive proposition for arrays and would be extremely costly with deep sequencing even at the as-yet unattained goal of $1000/genome.
Comprehensive genotyping of targeted genes, by arrays or sequencing, takes advantage of high multiplex assay capacities to saturate targets with genetic markers. Hence, array data are less reliant on capturing a single, important linked marker while retaining rapid sample throughputs, and sequencing costs and efficiency are improved by focusing on a subset of genes rather than the whole genome. Depending on the size of the target panel and degree of saturation desired, custom arrays or sequencing can ease multiple testing penalties and reduce study population sizes necessary to achieve statistical power. Of course, the critical issue for this strategy is choosing which genes to assay. For the LungCaGxE panel, we chose genes involved in pathways relevant to responses to environmental stressors and saturated the resulting target panel with genetic markers as well as previously demonstrated functional and diseaseassociated variants.
The Illumina design score, whereas generally predictive of positive assay performance, underestimated the LungCaGxE genotype success rate achieved for Infiniumeligible tagSNPs and custom SNPs from the nuclear genome. The design scores were somewhat less positively predictive (i.e., further underestimated) of genotyping rates achieved for mitochondrial genome SNPs, which performed well over a wide range of design scores. The rela- Distribution of assay conversion rates for SNPs in various design categories. Assays were assigned to Infinium design score bins equal to or less than the indicated values. The percent of all assays in a bin that successfully generated genotypes (unambiguous SNP allele calls in at least 95% of DNA samples) is plotted for Infinium-eligible SNPs in the Illumina database (black bars), mitochondrial DNA SNPs (gray bars), and SNPs uploaded as custom sequences (dashed bars). The number of SNPs in each bin, as a percent of total SNPs in each category, is plotted with square line markers for Infinium database SNPs, circles for mitochondrial, and X for custom sequences.
tively high success rates for assays with design scores Ͻ0.6 indicate that for future targeted genotyping projects, failure to meet this overly stringent standard cutoff should not necessarily disqualify an assay if the specific SNP in question is important for the study goals.
In summary, the investigator tasked with designing a custom-targeted genotyping assay must balance several considerations. Given that the platform's multiplex capacity is often dictated by the project's budget, the investigator must select the marker types, thresholds for number of genes targeted, and MAF cutoffs that will provide the most efficient use of available assay resources. Several iterations of empirical design are usually needed to assess the impact of these parameters, and this process is aided by a streamlined bioinformatics workflow. Tagger Batch Assistant helps automate the retrieval of genetic coordinates for requested genes, managing genome build versions and providing an output format that easily interfaces with Tagger for marker prediction. The resulting Tagger files are then automatically processed to connect markers with the user's upstream gene annotations. We used this tool to optimize the LungCaGxE design through multiple versions, preserving sensitivity for marker MAFs as low as 1%, while reducing the number of SNPs required by using the Tagger multimarker haplotyping algorithm. This array enables rapid, cost-effective, and comprehensive genotyping of a panel of genes important for exploring genetic factors in lung cancer and the environmental influences that impact those factors.
